In addition, targeting both FAK and HER2 resulted in a remarkable reduction in Akt and MAPK activity together with an increased amount of PARP cleavage, leading to the growth inhibition and death of ER+/HER2+ breast cancer cells [227]. This evidence concerns the gene ESR1 and breast carcinoma.